Answer
Entrectinib’s major active metabolite M5 inhibits TRK, ROS1 and ALK kinases, showing similar in vitro potency and activity to entrectinib.
Sources for this answer
- Rozlytrek 100 mg & 200 mg hard capsulesRoche Products Limited · emc · SmPC §5.1 Pharmacodynamic properties · Version 16Document updated
Sources checked